Loading…
Loading…
Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. The certification, part of Thermo Fisher's Life Sciences Solutions network, enables Verici Dx to support biomarker discovery, algorithm development, validation, clinical trials and diagnostic applications for both external clients and its own development pipeline.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Company also received NY state approval of Tutivia™, its blood-based laboratory developed test (LDT) that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score c.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assa.
Verici Dx PLC (AIM:VRCI) shares were up as much as 11% in early trading after the diagnostics company announced it had successfully completed its second biennial inspection by the College of American Pathologists (CAP), one of the leading US bodies for clinical laboratory accreditation. The inspection passed with no deficiencies, confirming the company's continued compliance with CAP's rigorous quality and operational standards.
Verici Dx PLC (AIM:VRCI) shares skipped 12% higher to 0.7p after the developer of diagnostic tests for organ transplants bagged a new agreement with a healthcare network in the United States. The deal with Prime Health Services sees Verici Dx join a preferred provider network, giving its services access to more than 850,000 healthcare providers and 35 million insurance claims a year.
Shares in Verici Dx PLC (AIM:VRCI) surged 23% in early trading on Monday after the diagnostics company reported encouraging progress in the commercial rollout of its Tutivia test for kidney transplant patients and announced changes to its board. The London-listed group said it had onboarded nine new transplant centres in the United States during the third quarter, taking the total to 30.
Verici Dx PLC (AIM:VRCI) is preparing to raise new equity funding as it looks to ramp up the commercial rollout of its flagship transplant diagnostic, Tutivia, in the US following a key Medicare coverage decision. The London-listed diagnostics firm said it had received early support from institutional backers and other investors for the planned fundraising, which will include a placing and a retail offer for existing shareholders.
Verici Dx PLC (AIM:VRCI) shares soared in Thursday morning's trade as the med-tech firm confirmed it had secured Medicare coverage for its Tutivia assay product. It comes as a technical assessment validated Tutivia.
No recent filings indexed.